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Infantile spasms (IS) is a relatively common and severe epilepsy of infants and young
children. IS likely contributes to up to 10% of all mental retardation, and it evolves into
further epilepsies in about 50% of cases.1 Although this catastrophic epilepsy was first
identified more than 160 years ago, its cause and mechanism are poorly understood and
treatment is unsatisfactory, particularly in preventing the postulated effects of these seizures
on cognitive function.1,2
These questions are difficult to address in human studies; thus, valid animal models for IS
are needed.3 However, defining and characterizing suitable models for IS has been a
daunting problem. Prominent among the issues facing investigators interested in developing
a model for IS are the numerous causes of this disorder: IS occurs in infants with metabolic
disorders, many gene mutations, brain malformations, tuberous sclerosis, congenital or
postnatal infections and strokes, among other causes. This multitude of apparent “causes”
has made it difficult to sort out the essential elements within any of these entities that are
required and sufficient to provoke IS.4,5
Models for IS proposed to date fit one of two general categories: those that recapitulate a
specific cause of IS (eg, loss of interneurons in the ARX mouse, artificial stroke/
hemispherectomy), and models that attempt to define and recreate a “final common
pathway” for all of the causes that elicit IS. This latter approach has been taken by Velisek's
group,6 as described in this issue of Annals.
The unusual, rapid, and robust response to adrenocorticotropic hormone (ACTH), the
current recommended therapy,7 has been considered a crucial clue for defining a common or
converging mechanism for IS.4,8,9 Because ACTH is a component of the neuroendocrine
stress response the possibility was raised that the common denominator or “final common
pathway” of the many causes of IS involves stress response within the developing brain.
Activation of specific components of the stress response, in turn, may promote
hyperexcitability and provoke the abnormal neuronal activity (hypsarrhythmia) and seizures
(spasms).4,10,11
The neuropeptide corticotropin-releasing hormone (CRH) is an attractive candidate as a
stress-activated convulsant that may contribute to the mechanisms of IS. It is released from
hippocampal,12 amygdalal,13 and certain brainstem14 neurons in response to stress and
promotes neuronal excitability,10 at least in part by reducing afterhyperpolarization.15
Therefore, the stress/CRH hypothesis of IS proposes that a common factor in patients with
this disorder is excess secretion of CRH in limbic and brainstem regions,16 which triggers
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the seizures. In this scenario, ACTH does not act as a direct anticonvulsant, but rather
ameliorates IS by reducing the synthesis and release of endogenous CRH.11 In essence,
ACTH functions as a true antiepileptic drug. This mechanism of action of ACTH is
consistent with the time course of its efficacy in infantile spasms,17 where response is often
all or none, requires a day or two to start, and often continues even when ACTH treatment is
terminated.17
Several characteristics of patients with IS support this pathophysiological model of IS4:
Infants with IS have low levels of ACTH in their cerebrospinal fluid.18–20 In addition, IS
improves with doses of ACTH that are much greater than those required to fully activate the
infant's adrenal gland to elicit secretion of maximal levels of endogenous glucocorticoids.
Indeed, the efficacy of high-dose ACTH is twice that of lower doses of this hormone or of
prednisone (86 – 88% vs 37–40%17,21). This enhanced efficacy strongly supports additional
mechanisms of action of this hormone, in addition to the release of glucocorticoids. The
possibility that ACTH may penetrate the blood–brain barrier, enter the brain, and exert
direct effects there has been demonstrated in animal models.5,11 In an immature rodent
model, systemic administration of high doses of ACTH leads to its entry into the central
nervous system, where it reduces the expression of the stress-activated excitatory peptide,
CRH, in limbic structures. Because CRH can evoke seizures in rodents and is released
during stress, this reduction of CRH levels provides a plausible mechanism for the actions of
ACTH on IS. Importantly, it defines potential molecular targets for the treatment of IS,
including compounds that, like ACTH, activate the melanocortin receptors or compounds
that directly block CRH receptors.1,11
In this issue of Annals, Velisek and colleagues6 present an interesting variant of the “stress-
evoked” infantile spasms story. A number of years ago, the authors discovered that
administration of NMDA to infant rats caused a flexion myoclonus.22 This was reminiscent
behaviorally of flexion spasms, the most common type of seizures in infants with IS,2 and
prompted the group to pursue this finding as a model for IS.
Whereas the NMDA-evoked movements resemble behavioral spasms, the commonality of
mechanisms between NMDA-evoked seizures and IS had previously remained unexplored.
A logical approach to examining whether there might be a common patho-physiology
involves demonstrating a therapeutic response profile of “NMDA spasms” that mirrors IS.
However, ACTH was not helpful for NMDA-evoked seizures given by the authors only
immediately before NMDA. This fact should not be surprising, because ACTH does not
have immediate effects on spasms in humans: the time of onset to its efficacy is measured in
days (median, approximately 2 days).17 In this context, it may be noted that ACTH also does
not block kindling23 or seizures induced by synthetic CRH in an infant rat model of IS.24
These findings are expected because ACTH likely acts by reducing the levels of endogenous
CRH.11
In this issue, Velisek and colleagues6 aim to refine their model by introducing an element of
prenatal stress into the factors provoking spasmlike seizures. Rather than stressing pups in
utero, they inject pregnant rats with a synthetic glucocorticoid. This approach might be
criticized for several reasons. First, it is not clear that the major means by which stress
influences the developing brain depends on glucocorticoids alone.25 In addition, the doses of
steroids used are high enough to adversely influence the weight, and hence brain
development, of the pups. Reduced body and brain weights are not typical in infants with IS.
This prenatal treatment rendered the NMDA-provoked seizures minimally responsive to
ACTH, with modest changes in latency. Although the authors consider this an important
validation of their model, this response is surprising, because it occurs within minutes of
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administration of ACTH, and not hours to days, as would be expected from a putative
mechanism of action via suppression of CRH expression. Therefore, the mechanisms by
which ACTH administration modifies the latency to NMDA-provoked seizures are not clear
and may involve direct actions within the central nervous system or peripheral effects on
glucocorticoid release from the adrenal gland. Glucocorticoids can both enhance and reduce
neuronal excitability.26,27
IS is a relatively common and intractable disorder, without optimal therapy. Therefore, new
efforts to understand its underlying mechanisms and model it in experimental organisms
deserve our attention and support. It is hoped that, among the several new suggested models
for this disorder,28–30 one or more will emerge as a powerful tool that will facilitate the
cure, and perhaps even the prevention, of this devastating developmental epilepsy.
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